Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 19 Jan 2016 |
| Daratumumab Data Published in The Lancet Shows Encouraging Efficacy in Heavily Pretreated and Refractory Multiple Myeloma | 7 Jan 2016 |
| Genmab Announces Completion of Agreement to Transfer Remaining Ofatumumab Rights | 21 Dec 2015 |
| Genmab Achieves $3 Million Milestone in DuoBody Platform Collaboration with Janssen | 21 Dec 2015 |
| Articles of Association for Genmab A/S | 18 Dec 2015 |